caa a22 4500 445335106 CHVBK 20180317142752.0 cr unu---uuuuu 170323e20110301xx s 000 0 eng 10.1245/s10434-010-1425-1 doi (NATIONALLICENCE)springer-10.1245/s10434-010-1425-1 Treatment and Outcome of Patients with Gastric Remnant Cancer After Resection for Peptic Ulcer Disease [Elektronische Daten] [James Mezhir, Mithat Gonen, John Ammori, Vivian Strong, Murray Brennan, Daniel Coit] Background: To study the pathology, treatment, and outcome of patients with gastric remnant cancer (GRC) after resection for peptic ulcer disease (PUD). Methods: Review of a prospective gastric cancer database identified patients with GRC after gastrectomy for PUD. Clinicopathologic and treatment-related variables were obtained. Multivariate analysis was performed for factors associated with disease-specific survival (DSS). Results: From January 1985 to April 2010, 4402 patients with gastric adenocarcinoma were treated at our institution and 105 patients (2.4%) had prior gastrectomy for PUD. Prior resections were most often Billroth II (N=97, 92%). The median time from initial resection to development of GRC was 32years (3-60years), and the majority of tumors were located at the gastrointestinal anastomosis (N=72, 69%). Median DSS was 1.3years (0.6-2.1years). Patients who had resection had a significantly better outcome than patients who did not have resection (median DSS 5 vs 0.35years, P<.0001). Factors associated with DSS on multivariate analysis included advanced T-stage (HR 16.5 (CI 2.2-123.4), P=.0006) and lymph node metastasis (HR 1.1 (CI 1.0-1.2), P<.0001). Stage-specific survival following R0 resection was similar to patients with conventional gastric cancer. Conclusions: Patients have a lifetime risk for the development of GRC following resection for PUD. As with conventional gastric cancer, determinants of survival of patients with GRC include advanced T stage and nodal metastasis. Patients with GRC amenable to curative resection exhibit the best DSS and have stage-specific outcomes similar to patients with conventional gastric cancer. Society of Surgical Oncology, 2010 Mezhir James Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut Gonen Mithat Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut Ammori John Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut Strong Vivian Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut Brennan Murray Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut Coit Daniel Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut Annals of Surgical Oncology Springer-Verlag 18/3(2011-03-01), 670-676 1068-9265 18:3<670 2011 18 10434 https://doi.org/10.1245/s10434-010-1425-1 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1425-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Mezhir James Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut NATIONALLICENCE 700 1- Gonen Mithat Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut NATIONALLICENCE 700 1- Ammori John Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut NATIONALLICENCE 700 1- Strong Vivian Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut NATIONALLICENCE 700 1- Brennan Murray Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut NATIONALLICENCE 700 1- Coit Daniel Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/3(2011-03-01), 670-676 1068-9265 18:3<670 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer